Journal
BIOLOGICAL PSYCHIATRY
Volume 83, Issue 4, Pages 320-327Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2017.08.001
Keywords
Alzheimer; Amyloid-beta; beta-Secretase; gamma-Secretase; Prevention; Therapy
Categories
Funding
- Stichting Alzheimer Onderzoek
- Fund for Scientific Research, Flanders
- KU Leuven
- Methusalem grant from the KU Leuven
- Flemish Government
- Interuniversity Attraction Poles Program of the Belgian Federal Science Policy Office
- Vlaams Initiatief voor Netwerken voor Dementie Onderzoek (Strategic Basic Research) [135043]
- Arthur Bax and Anna Vanluffelen chair for Alzheimer's disease
- Opening the Future of the Leuven Universiteit Fonds
- Medical Research Council [MC_PC_17116] Funding Source: researchfish
- MRC [MC_PC_17116] Funding Source: UKRI
Ask authors/readers for more resources
The genetic evidence implicating amyloid-beta in the initial stage of Alzheimer's disease is unequivocal. However, the long biochemical and cellular prodromal phases of the disease suggest that dementia is the result of a series of molecular and cellular cascades whose nature and connections remain unknown. Therefore, it is unlikely that treatments directed at amyloid-b will have major clinical effects in the later stages of the disease. We discuss the two major candidate therapeutic targets to lower amyloid-b in a preventive mode, i.e., gamma- and beta-secretase; the rationale behind these two targets; and the current state of the field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available